Aethlon Medical
NASDAQ: AEMDSan Diego, US · Nevada corporation
Find your way into Aethlon Medical
Aethlon Medical develops the Hemopurifier, a clinical-stage extracorporeal device that uses lectin-based technology to remove extracellular vesicles and enveloped viruses from blood plasma, with current clinical programs targeting patients with advanced cancer resistant to immunotherapy and potential applications in life-threatening viral infections. The company is advancing safety and feasibility trials in Australia for cancer treatment and maintains regulatory pathways for viral indications while exploring additional disease applications through preclinical research.
Founders & leadership
RH
Richard H. TullisFounder
JB
James B. FrakesExecutive
RS
Rodney S. KenleyExecutive
JJ
James JoyceinPresident/CEOformer
SP
Steven P. LaRosainChief Medical OfficerSteven P. LaRosa is Chief Medical Officer of Aethlon Medical and holds a medical degree from Boston University School of Medicine with board certifications in internal medicine and infectious disease. He brings 28 years of clinical development experience in biotechnology and pharma across infectious diseases, oncology, and medical devices, including 5.5 years as CMO at a NASDAQ-traded biotech company and 19 years of infectious disease clinical practice at academic medical centers including Cleveland Clinic and Massachusetts General Hospital.
RH
RICHARD H. TULLIS, PhDNamed on SEC filing
Board
CS
Chetan S. Shah, M.D.Board director
EG
Edward G. BroennimanBoard director
NG
Nicolas GikakisBoard director
AR
Angela RossettiBoard director
FS
Franklyn S. Barry, Jr.Board director
CS
CHETAN SHAH, MDBoard director
Reported raises · per SEC filings
Form D private placements$20.2M disclosed across 10 rounds · 2011–2025
▶$2.2MraisedDec 2025 · 1 investors · BiotechnologyRule 506(b)
▶$2.2MraisedDec 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chetan S. Shah, M.D.Director
- James B. FrakesExecutive Officer, Director
- Edward G. BroennimanDirector
- Nicolas GikakisDirector
- Angela RossettiDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Sales commissions
- $214.5K
- First sale
- Dec 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.7MraisedJan 2020 · 7 investors · BiotechnologyRule 506(b)
▶$2.7MraisedJan 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- TIMOTHY C. RODELLExecutive Officer, Director
- SABRINA MARTUCCI JOHNSONDirector
- EDWARD G. BROENNIMANDirector
- CHARLES J. FISHERDirector
- CHETAN S. SHAHDirector
- JAMES B. FRAKESExecutive Officer
- GUY CIPRIANIDirector
- Offering amount
- $2.7M
- Amount sold
- $2.7M
- Sales commissions
- $226.2K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$6MraisedJul 2015 · 19 investors · BiotechnologyRule 506(b)
▶$6MraisedJul 2015 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- RODNEY S. KENLEYExecutive Officer, Director
- FRANKLYN S. BARRY, JR.Director
- JAMES B. FRAKESExecutive Officer
- EDWARD G. BROENNIMANDirector
- RICHARD H. TULLIS, PhDExecutive Officer
- JAMES A. JOYCEExecutive Officer, Director
- CHETAN SHAH, MDDirector
- Offering amount
- $6M
- Amount sold
- $6M
- Sales commissions
- $360.5K
- Placement agents
- ROTH Capital Partners, LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.3MraisedDec 2014 · 4 investors · BiotechnologyRule 506(b)
▶$3.3MraisedDec 2014 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James B. FrakesExecutive Officer
- Rodney S. KenleyExecutive Officer, Director
- Franklyn S. Barry, Jr.Director
- James A. JoyceExecutive Officer, Director
- Edward G. BroennimanDirector
- Richard H. Tullis, PhDExecutive Officer, Director
- Chetan Shah, MDDirector
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- Sales commissions
- $256K
- Placement agents
- ROTH Capital Partners, LLC
- First sale
- Dec 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$527.8KraisedNov 2014 · 2 investors · BiotechnologyRule 506(b)
▶$527.8KraisedNov 2014 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rodney S. KenleyExecutive Officer, Director
- Franklyn S. Barry, Jr.Director
- Richard H. Tulls, PhDExecutive Officer, Director
- James B. FrakesExecutive Officer
- Chetan Shah, MDDirector
- Edward G. BroennimanDirector
- James A. JoyceExecutive Officer, Director
- Offering amount
- $527.8K
- Amount sold
- $527.8K
- First sale
- Nov 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$837.7KraisedNov 2014 · 3 investors · BiotechnologyRule 506(b)
▶$837.7KraisedNov 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAMES A. JOYCEExecutive Officer, Director
- RODNEY S. KENLEYExecutive Officer, Director
- FRANKLYN S. BARRY, JR.Director
- RICHARD H. TULLIS, PhDExecutive Officer, Director
- CHETAN SHAH, MDDirector
- JAMES B. FRAKESExecutive Officer
- EDWARD G. BROENNIMANDirector
- Offering amount
- $837.7K
- Amount sold
- $837.7K
- First sale
- Oct 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$838.7KraisedNov 2014 · 9 investors · BiotechnologyRule 506(b)
▶$838.7KraisedNov 2014 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAMES B. FRAKESExecutive Officer
- FRANKLYN S. BARRY, JR.Director
- EDWARD G. BROENNIMANDirector
- RICHARD H. TULLIS, PhDExecutive Officer, Director
- JAMES A. JOYCEExecutive Officer, Director
- RODNEY S. KENLEYExecutive Officer, Director
- CHETAN SHAH, MDDirector
- Offering amount
- $838.7K
- Amount sold
- $838.7K
- First sale
- Jul 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$913.5KraisedNov 2014 · 14 investors · BiotechnologyRule 506(b)
▶$913.5KraisedNov 2014 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- EDWARD G. BROENNIMANDirector
- RICHARD H. TULLIS, PhDExecutive Officer, Director
- RODNEY S. KENLEYExecutive Officer, Director
- CHETAN SHAH, MDDirector
- JAMES A. JOYCEExecutive Officer, Director
- FRANKLYN S. BARRY, JR.Director
- JAMES B. FRAKESExecutive Officer
- Offering amount
- $913.5K
- Amount sold
- $913.5K
- Minimum investment
- $10K
- First sale
- May 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
TradingView15 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Robinhood14 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha12 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwits12 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Public11 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies competing with Aethlon Medical for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $298.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $299.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Aethlon Medical do?
- Aethlon Medical develops the Hemopurifier, a clinical-stage extracorporeal device that uses lectin-based technology to remove extracellular vesicles and enveloped viruses from blood plasma, with current clinical programs targeting patients with advanced cancer resistant to immunotherapy and potential applications in life-threatening viral infections. The company is advancing safety and feasibility trials in Australia for cancer treatment and maintains regulatory pathways for viral indications while exploring additional disease applications through preclinical research.
- Who founded Aethlon Medical?
- Aethlon Medical was founded by Richard H. Tullis.
- How much funding has Aethlon Medical raised?
- Aethlon Medical has disclosed $20.2M raised across 10 rounds.
- Where is Aethlon Medical headquartered?
- Aethlon Medical is headquartered in San Diego, US.